International Severe Asthma Registry – ISAR
What is ISAR?
The International Severe Asthma Registry is a global collaborative initiative to gather anonymous, longitudinal, real-life data for patients with severe asthma from 25 countries. ISAR offers a rich source of real-life data for scientific research to understand and improve symptoms, treatments, and patient outcomes for severe asthma. The database will also provide an international platform for research collaboration in respiratory medicine and patient care.
-
Optimum Patient Global
Co-sponsorship, project management and delivery
-
AstraZeneca
Co-sponsorship
-
Respiratory Effectiveness Group
Academic partner
-
Observational Pragmatic Research Institute
Country-specific registries
ENCEPP database registration: http://www.encepp.eu/encepp/viewResource.htm?id=24389
What are the ISAR goals?
The goals of ISAR are to:
- Standardise and integrate data collection by using a core set of variables across all participating countries. Variables were selected using a modified Delphi process [1]
- Support data collection – electronic data capture, hosting and data entry
- Enable collaborating countries to answer key research questions in severe asthma on a global scale
- Improve the care of severe asthma patients
ISAR is governed by four independent bodies:
- ISAR steering committee: Renowned researchers in the field of severe asthma from 25 countries and 4 AZ members
- Respiratory Effectiveness Group (REG): Academic partner and international experts in severe asthma
- ADEPT committee: Researchers into ethical oversight (operational for the past five years) and senior researchers with clinical, epidemiological and/or database expertise
- Operational committee: Participating country representatives
If you would like more information about the ISAR registry, why not contact us or take a look at the ISAR website.
ISAR Progress
12,764
Total number of patients
10,020
Prospective patient-level data
13,150
Target for prospective patient recruitment by December 2023 with severe asthma
Agreements executed
Agreements in progress
Status as at March 2022
Argentina | n=129
Australia | n=671
Bulgaria | n=356
Canada | n=276
Colombia | n=301
Denmark | n=666
Greece | n=155
India | n=187
Ireland | n=42
Italy | n=1,540
Japan | n=197
Kuwait | n=303
Mexico | n=145
Poland | n=73
Portugal | n=141
Saudi Arabia | n=207
Singapore | n=10
Korea (Republic of) | n=165
Spain | n=715
Taiwan | n=292
United Arab Emirates | n=229
United Kingdom | n=714
United States of America | n=2,586
Patients are eligible for inclusion, into the ISAR Registry, if they have asthma requiring GINA Step 5 treatment or GINA Step 4 treatment and uncontrolled asthma.
-
Click here to see the full list of participating countries
Countries Lead Argentina Jorge Maspero Australia Matthew Peters Bulgaria George C. Christoff Canada J. Mark FitzGerald Colombia Carlos Torres Denmark Celeste M. Porsbjerg Germany Christian Taube Greece Andrianna I. Papaioannou India Sundeep Salvi Ireland Richard W. Costello Italy George Walter Canonica Enrico Heffler Japan Takashi Iwanaga Kuwait Mona Al-Ahmad Mexico Désirée Larenas Linnemann Poland Piotr Kuna Portugal João A Fonseca Saudi Arabia Riyard Al-Lehebi Singapore Mariko Koh Siyue South Korea Chin Kook Rhee Kwang Ha Yoo Spain Luis Perez-de-Llano Sweden David Aronsson Taiwan Steve Perng Diahn-Warng United Arab Emirates Bassam Mahboub United Kingdom Andrew Menzies-Gow Liam G. Heaney United States of America Eileen Wang -
Click here to learn more about ISAR research projects
Priority research topics by ISAR for 2021 are:
Phenotypic Characteristics, Comorbidities and Response to Therapeutic Interventions Associated with Non-Type 2 Asthma (EMBER)
Effectiveness of Biologics (by classes) in Patients with Different Combination of T2 Biomarkers (IGNITE)
To see the full list of research projects, please visit the ISAR website